Photocall of the merger between drug companies Glaxo Wellcome and SmithKline Beecham, in London. L-R: Sir Richard Sykes and Jean-Pierre Garnier. The agreed deal will create the world's largest pharmaceuticals group. * Sir Richard Sykes is Chairman of Glaxo Wellcome / Non-Executive Chairman of merged company, and Jean-Pierre Garnier is Chief Executive elect of SmithKline Beecham / Chief Executive of proposed merged company. The merger will create a company with a value of around 114 billion which will be one of Europe's largest by stock market value. 19/05/03 Shareholders were, expected to r

Photocall of the merger between drug companies Glaxo Wellcome and SmithKline Beecham, in London. L-R: Sir Richard Sykes and  Jean-Pierre Garnier. The agreed deal will create the world's largest pharmaceuticals group.  * Sir Richard Sykes is Chairman of Glaxo Wellcome / Non-Executive Chairman of merged company, and Jean-Pierre Garnier is Chief Executive elect of SmithKline Beecham / Chief Executive of proposed merged company. The merger will create a company with a value of around  114 billion which will be one of Europe's largest by stock market value. 19/05/03 Shareholders were, expected to r Stock Photo
Preview

Image details

Contributor:

PA Images / Alamy Stock Photo

Image ID:

2D30K27

File size:

5 MB (139.8 KB Compressed download)

Releases:

Model - no | Property - noDo I need a release?

Dimensions:

1636 x 1062 px | 27.7 x 18 cm | 10.9 x 7.1 inches | 150dpi

Date taken:

17 January 2000

Photographer:

Andrew Stuart

More information:

This image could have imperfections as it’s either historical or reportage.

Photocall of the merger between drug companies Glaxo Wellcome and SmithKline Beecham, in London. L-R: Sir Richard Sykes and Jean-Pierre Garnier. The agreed deal will create the world's largest pharmaceuticals group. * Sir Richard Sykes is Chairman of Glaxo Wellcome / Non-Executive Chairman of merged company, and Jean-Pierre Garnier is Chief Executive elect of SmithKline Beecham / Chief Executive of proposed merged company. The merger will create a company with a value of around 114 billion which will be one of Europe's largest by stock market value. 19/05/03 Shareholders were, expected to revolt over "fat cat" pay at GlaxoSmithKline's annual general meeting today. Mr Garnier, the firm's chief executive, was expecting criticism over his contract.

Available for Editorial use only.